Wearable Electromagnetic Headband Enters RCT for Treatment-Resistant Depression

Major depressive disorder affects millions globally and carries enormous personal and societal costs. Despite advances in pharmacotherapy and psychotherapy, a significant proportion of patients fail to achieve remission, driving interest in non-invasive neuromodulation approaches. Transcranial pulsed electromagnetic fields (T-PEMF) represent a lower-intensity alternative to repetitive transcranial magnetic stimulation (rTMS), operating at roughly 0.004 V/m compared to rTMS's 90 V/m, and delivering more diffuse, multi-focal stimulation across the scalp. Prior Danish studies — including one RCT and one single-arm multicentre study — reported positive antidepressant signals, though a 2021 Dutch double-blind RCT found no effect, possibly due to insufficient field strength. The current trial aims to resolve this uncertainty with a rigorously designed study using a novel device.

The MoodHeadBand (MHB) is a wearable silicone-gum headband containing 20 current-carrying coils (187 turns each, inner diameter 1.49 cm, outer diameter 2.29 cm), powered by a 5V power bank. Active devices generate a pulsating 55 Hz electromagnetic field with a maximum B-field of 15.9 Gauss and E-field of 50 mV/m at 1 cm from the coils. Sham devices are physically identical but deliver no stimulation. The device has not previously been tested in humans and is classified as a Class IIa medical device under EU directive 2017/745. Treatment sessions are 30 minutes daily, self-administered at home, over 8 weeks — a design that enhances accessibility for a population often challenged by clinic attendance.

The trial enrolls 96 participants (ages 18–65) with ICD-10 moderate-to-severe depression without psychotic features, randomized 1:1 to active or sham MHB. Randomization is stratified by baseline antidepressant use, with allocation concealed in a sealed envelope held by the sponsor. Both participants and research personnel are blinded; device identity is managed by the manufacturer using coded identification numbers. All participants continue standard Danish depression care (antidepressants and/or psychotherapy) throughout, which is tracked as a potential confounder. Weekly follow-ups occur in person, by video, or telephone.

The primary outcome is change in the Inventory of Depressive Symptomatology Self-Report (IDS-SR) from baseline to week 8. Secondary outcomes include Hamilton Depression Rating Scale-17 (HAM-D-17) scores, cognitive performance across emotion-laden and non-emotion-laden neuropsychological tests (assessed at baseline, week 1, and week 8), and sleep quality via weekly sleep logs and the Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR). A key secondary hypothesis is whether early changes in emotional cognition at week 1 can predict antidepressant response at week 8 — a clinically meaningful question for treatment personalization. Statistical approaches include generalized linear models, mixed model repeated measures, and Kaplan-Meier survival analysis.

The trial's mechanistic rationale draws on a 2023 study showing T-PEMF promotes cell proliferation, angiogenesis, and anti-apoptotic signaling via microglial secretion of VEGF, IL-8, and GLP-1 — pathways increasingly implicated in depression neurobiology. Safety data from prior T-PEMF studies are reassuring: side effects have been mild and transient (headache, slight nausea), with no significant differences between active and sham groups, no delayed adverse events, and no manic switches reported. Limitations include the absence of long-term follow-up, potential confounding from concurrent antidepressant and psychotherapy use, and a conflict of interest in that the device inventor co-owns the manufacturing company and partially funded a researcher's salary.